Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
The company showcased three core programs developed through this platform
These medicines are essential in preventing RhD immunisation during pregnancy
Commercial production is expected to begin soon
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
The audit has been concluded with no major observations
Subscribe To Our Newsletter & Stay Updated
